Daily Archives: July 5, 2018

Faecalibacterium prausnitzii a member of the Clostridium IV group of the Firmicutes phylum that is abundant in the intestinal microbiota, has anti-inflammatory effects. The relative level of F prausnitzii is decreased in fecal samples from patients wit… Continue reading →

Screening patients with cirrhosis for hepatocellular carcinoma (HCC) has been recommended. We conducted a matched case–control study within the US Veterans Affairs (VA) healthcare system to determine whether screening by abdominal ultrasonography (US… Continue reading →

In 2 prospective cohorts, histologic grade of intestinal metaplasia before radiofrequency ablation for Barrett’s esophagus predicts recurrent neoplasia and can be used to determine surveillance intervals. Continue reading →

Recently, Li et al1 have reported that vein injection of nanoliposome C6-ceramide, a cell membrane permeable form of ceramide, slows growth of liver tumors in mice, through suppressing tumor-associated macrophage functions and enhancing tumor antigen-… Continue reading →

Thank you for the first letter commenting on our paper. In a case of pulmonary arterial hypertension (PAH) occurring in patients with ulcerative colitis (UC) under indigo naturalis treatment, PAH was associated with patients with UC after using indigo … Continue reading →

We read with great interest the recent article by Naganuma et al.1 The authors showed a significant effect of indigo naturalis in treating patients with ulcerative colitis (UC) in a randomized, placebo-controlled trial. In their study, patients were randomly assigned to groups given a daily dose of 0.5, 1.0, or 2.0 g of indigo naturalis or placebo for 8 weeks. The proportion of patients with a clinical response at week 8 was significantly higher in the 0.5-g indigo naturalis group (69.6%; P = .0002), 1.0-g indigo naturalis group (75.0%; P = .0001), and 2.0-g indigo naturalis group (81.0%; P < .0001) than in the placebo group (13.6%). Continue reading →